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Polycystic ovary syndrome (PCOS) is the most com-mon endocrine pathology in women of reproductive age, 
affecting 5% to 10% of the population, often beginning in ado-
lescence.1–3 PCOS in young women is characterized by hyper-
androgenemia, modest increases in blood pressure, insulin 
resistance, and increased inflammation.2–4 With aging, hyper-
androgenemia does not abate, even following menopause.5–7 
The clinical guidelines for PCOS diagnosis have only been in 
place since 2002 to 20041; thus there are few studies that have 
focused on the consequences of aging (ie, post-menopause) on 
cardiovascular disease (CVD) risk in PCOS women, due to the 
lack of aging populations in which PCOS had been definitively 
diagnosed, that is, with androgen measurements. Furthermore, 
to our knowledge, there are no studies in which the effect of 
prior pregnancy on postmenopausal CVD and hypertension in 
PCOS women has been studied.
PCOS women may have difficulty becoming pregnant and 
have a higher incidence of requiring assisted reproduction, 
such as in vitro fertilization.8,9 Persson et al8 reported that 
Scandinavian PCOS women take longer to become pregnant 
and have fewer children than women without PCOS, but once 
pregnant, the probability of childbirth was similar in PCOS 
women versus controls. Hu et al10 reported that PCOS women 
had elevated blood pressure during pregnancy, as measured by 
ambulatory recording, but there were no data on prepregnancy 
blood pressures, nor did the blood pressures reach guideline 
levels required for treatment of hypertension.
One may surmise that exposure to cardiovascular and met-
abolic risk factors throughout the entirety of their reproduc-
tive lives would predispose PCOS women to early CVD risk. 
However, this supposition is controversial.11–14 For example, 
recent reviews question whether women with PCOS have 
greater morbidity and mortality than the general population 
of postmenopausal women, and point out that data are scarce 
as to the postmenopausal health of PCOS women, and even 
suggest that PCOS women are not different from the general 
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population or actually may be protected from CVD.11,15–17 One 
study showed that PCOS women go through menopause 4 
years later than age-matched controls,18 which may imply pro-
tection from CVD due to longer exposure to estradiol.
In recent years, we have studied the hyperandrogenemic 
female (HAF) rat that mimics many of the characteristics of 
women with PCOS.19 Female Sprague-Dawley rats are given 
dihydrotestosterone, beginning shortly after weaning and con-
tinued throughout their lives19; dihydrotestosterone is used since 
it cannot be converted to estradiol. The serum levels of androgens 
are similar to levels found in PCOS women and do not affect 
endogenous synthesis of testosterone and estradiol.19 By 14 to 
16 weeks of age, HAF rats develop obesity, hyperlipidemia, in-
sulin resistance, inflammation, and elevated blood pressure.19 
We found that the elevated blood pressure in the young HAF rat 
is mediated in part by increased intrarenal vascular 20-HETE,20 
and increased sympathetic activation.21 We have also char-
acterized the HAF rats as they stop estrous cycling, by 12 to 
13 months of age.22 Blood pressure continues to increase with 
aging in HAF rats, and they become hypertensive.22
Thus using the HAF rat model in the current study, we tested 
the hypothesis that pregnancy would protect against the hyper-
tension that occurs in virgin HAF rats with aging (16 months 
of age) and evaluated the intrarenal mRNA expression of genes 
known to contribute to postmenopausal hypertension, such as 
the nitric oxide (NO) pathway, the renin-angiotensin system, 
and the endothelin system. We also determined if differences in 
blood pressure occurred at 10 months of age before cessation 
of estrous cycling, and whether there were differences in body 
composition that occurred during pregnancy or with aging that 
could impact blood pressure in HAF rats.
Materials and Methods
The data from this work are available from the corresponding author 
upon reasonable request.
Animal Model
Female Sprague-Dawley rats were obtained at 3 weeks of age from the 
vendor (Envigo, Indianapolis, IN) and allowed to equilibrate in a temper-
ature-controlled environment with 12-hour:12-hour light:dark cycle for 1 
week. As shown in Figure S1A and S1B in the Data Supplement, rats were 
randomly selected to be implanted with either 5α-dihydrotestosterone or 
placebo pellets to generate HAF or controls, respectively, as we previ-
ously described.19,22 All protocols followed the ARRIVE Guidelines and 
were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of Mississippi Medical Center and com-
plied with the Guidelines for the Care and Use of Laboratory Animals by 
the National Institutes of Health.
Estrous Cycle and Pregnancy
HAF rats exhibited a 6-day estrous cycle rather than the typical 
4-day cycle as found in controls.19,22 In separate groups of rats and 
as shown in Figure S1A and S1B, at 2 months of age, body com-
position (lean and fat mass) was measured in HAF and control rats 
(n=4–14/group) by echo-magnetic resonance imaging23 (Methods in 
the Data Supplement) and then at 2.5 to 3 months of age, HAF and 
control rats were paired with Sprague-Dawley males. Pregnancies 
occurred in ≈60% of HAF rats and 99% of control rats. When preg-
nancy was detected, as denoted by increased body weight, males were 
removed from the cage. HAF and control dams were allowed to de-
liver, and within 12 hours of delivery, the number of pups in each 
litter (both control and HAF) were counted (n=16–25 litters/group), 
body weights were obtained, and anogenital distances were measured 
to differentiate males from females (≈3–4 mm in males and ≈1–2 mm 
in females). Pups were reweighed at 48 hours. The weights of male 
and female pups were averaged per litter at both time points and were 
then averaged as groups: male control, male HAF, female control, and 
female HAF pups. All dams were allowed to suckle their pups, and 
pups were weaned at 21 days of age.
In a separate group of rats, body composition was measured be-
fore pregnancy in HAF rats and in age-matched controls (noted a-
bove), as shown in Figure S1A and S1B, and body composition was 
measured again by echo-magnetic resonance imaging 2 days post-
partum in HAF and control rats and compared to age-matched virgin 
controls and HAF rats.
Aging Protocols
As shown in Figure S1A and S1B, following weaning of the pups, 
control and HAF previously pregnant rats were allowed to age to 
10 or 16 months (n=4–16/group). Age-matched HAF and control 
virgins were also allowed to age to 10 or 16 months. At 10 and 16 
months of age, 24-hour urine collections were made for measure-
ment of protein and nitrate/nitrite excretion in virgin and previously 
pregnant HAF rats, as we previously described23,24 (Methods in the 
Data Supplement). Body composition and oral glucose tolerance 
were also measured at 10 and 16 months of age in HAF virgins and 
previously pregnant rats, as previously described.23 Mean arterial 
pressure (MAP), systolic, and diastolic blood pressure were meas-
ured by radiotelemetry for 4 days at 10 and 16 months of age in both 
virgin and previously pregnant HAF and control rats, as previously 
described (Methods in the Data Supplement).
Upon completion of MAP in 16 months old virgin and previously 
pregnant HAF rats (n=6/group), blood samples were taken for plasma 
dihydrotestosterone and insulin that were measured as we previously 
described23 (Methods in the Data Supplement). In additional group of 
rats, kidneys from virgin and previously pregnant control and HAF 
rats removed and flash-frozen in liquid nitrogen for real-time quanti-
tative polymerase chain reaction measurement of mRNA.
Gene Expression
To determine mRNA expression of genes in systems that are known 
to play a role in blood pressure control, quantitative polymerase 
chain reaction was performed in kidneys from virgin and previously 
pregnant control and HAF rats (n=6–12/group), as we previously 
described23 (Methods in the Data Supplement). The data for eNOS 
(endothelial nitric oxide synthase), renin, angiotensinogen, ACE 
(angiotensin-converting enzyme), AT1aR (angiotensin 1a receptor), 
pre-pro-ET-1 (endothelin), ET
A
 receptor (R), and ET
B
R (endothelin B 
receptor) were factored for the geometric mean of four housekeeping 
genes (shown in Figure S2).
Statistical Analyses
All data are expressed as means±SEM. Two-way ANOVA was used 
to determine the differences among groups in most studies. For the 
data in Tables 1 and 2, 2-way ANOVA with repeated measures was 
used. The Student t test was used to determine differences in number 
of pups per litter, plasma dihydrotestosterone, and insulin levels, 
body weight gains prepregnancy and postpregnancy. Uncorrected 
Fisher LSD test was used for post hoc tests when necessary. Values of 
P≤0.05 were considered statistically significant. Statistical analyses 
were performed using GraphPad Prism software (GraphPad Software 
Inc, V6.0c, San Diego, CA).
Results
Characteristics of the Offspring of HAF and 
Control Pregnancies
As shown in Figure 1A, there were no differences in the 
number of offspring per litter in HAF and control pregnan-
cies (control: 12±1; HAF: 11±1 pups/litter). Birth weights for 
both male and female HAF offspring were less than male or 
female offspring born to control dams (Figure 1B), and HAF 
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(Figure 1C). Female HAF offspring also weighed less than 
male HAF offspring at both ages (Figure 1B). These data sup-
port significant impacts of both androgens and sex on the dif-
ferences, but no interaction was noted.
Mean Arterial Pressure
As shown in Figure 2A, at 16 months of age, MAP in virgin HAF 
rats was higher than in other groups, and previous pregnancy at-
tenuated the hypertension in HAF rats. MAP in previously preg-
nant HAF rats was slightly higher than in previously pregnant 
control rats. Thus, there were significant impacts of both andro-
gens and parity on MAP at 16 months, but no interactions noted.
To determine whether there were differences in MAP be-
fore cessation of estrous cycling, MAP was measured in virgin 
and previously pregnant control and HAF rats, 10 months of 
age. As shown in Figure 2B, only androgens, not parity, im-
pacted the hypertension in HAF versus control rats, and there 
was no interaction noted.
When blood pressures were compared at 10 and 16 
months of age in HAF rats (Figure 2C), MAP was similar be-
tween virgin HAF at 10 months of age, previously pregnant 
HAF at 10 months of age, and previously pregnant HAF at 16 
months of age. Importantly, MAP increased significantly in 
virgin HAF rats between 10 and 16 months of age. There was 
significant interaction between age and parity in these studies.
Interestingly, as shown in Figure 2D and 2E, changes in 
systolic blood pressure rather than diastolic blood pressure 
Table 1. BW and Body Composition in Pregnant Control and HAF Rats Before Pregnancy and 48 Hours After Delivery
Parameter Pregnant Control (n=5) Pregnant HAF (n=3) Interaction Time Androgens
BW, g Prepregnancy 197.8±5.2 251.0±3.0* P=0.53 P<0.01 P<0.01
Postdelivery 263.6±12.3† 323.7±7.1*
BW gain during pregnancy, g 65.8±7.4 72.7±4.3    
Fat mass, g Prepregnancy 16.5±0.6 18.5±1.0 P=0.86 P=0.04 P=0.41
Postdelivery 21.7±2.5 22.9±1.6
Fat mass (% of BW) Prepregnancy 8.4±0.4 7.4±0.4 P=0.97 P=0.67 P=0.07
Postdelivery 8.2±0.6 7.1±0.4
Lean mass, g Prepregnancy 174.9±6.1 227.4±2.5* P=0.54 P<0.01 P<0.01
Postdelivery 232.2±10.1‡ 288.9±6.6*‡
Lean mass (% of BW) Prepregnancy 88.4±0.8 90.6±0.1* P=0.45 P=0.30 P=0.02
Postdelivery 88.1±0.4 89.3±0.2
Values represent mean±SEM. Fat and lean masses were determined by Echo-MRI as described in Methods. Statistical analyses by ANOVA with repeated measures 
and uncorrected Fisher LSD; significance was defined as P≤0.05. BW gain was compared by t test. BW indicates body weight; HAF, hyperandrogenemic female; and 
MRI, magnetic resonance imaging.
*P<0.05, compared with pregnant controls, P≤0.05.
†P<0.05 compared with virgin HAF.
‡P<0.05, compared with prepregnancy of the same group.
Table 2. BW and Body Composition in Pregnant and Virgin HAF Before Pregnancy and 48 Hours After Delivery
Parameter Age-Matched Virgin HAF (n=4) Pregnant HAF (n=3) Interaction Time Pregnancy
BW, g Prepregnancy 243.0±13.2 251.0±3.0 P=0.30 P<0.01 P=0.91
Postdelivery 327.3±7.1* 323.7±7.1*
BW gain during pregnancy, g 84.3±7.9 72.7±4.3    
Fat mass, g Prepregnancy 18.0±1.6 18.5±1.0 P=0.052 P<0.01 P=0.18
Postdelivery 32.8±3.8* 22.9±1.6*,†
Fat mass (% of BW) Prepregnancy 7.4±0.6 7.4±0.4 P=0.047 P=0.09 P=0.09
Postdelivery 10.0±0.8* 7.1±0.4†
Lean mass, g Prepregnancy 219.7±2.5 227.4±2.5 P=0.92 P<0.01 P=0.71
Postdelivery 282.1±17.8* 288.9±6.6*
Lean mass (% of BW) Prepregnancy 90.4±0.8 90.6±0.1 P<0.01 P<0.01 P=0.12
Postdelivery 86.1±0.8* 89.3±0.8*,†
Values represent mean±SEM. Fat and lean masses were determined by Echo-MRI as described in Methods. Statistical analyses by ANOVA with repeated measures 
and uncorrected Fisher LSD; significance was defined as P≤0.05. BW gain was compared by t test. BW indicates body weight; HAF, hyperandrogenemic female; and 
MRI, magnetic resonance imaging.
*P<0.05, compared with prepregnancy of the same group.
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accounted for the increased blood pressure in virgin HAF at 
16 months of age.
Potential Mechanisms That Could Contribute to 
Lower Blood Pressure in Previously Pregnant HAF 
Rats, Aged 16 Months
Dihydrotestosterone Levels
We have shown previously that dihydrotestosterone levels 
are increased ≈3-fold with dihydrotestosterone treatment 
compared with placebo controls.19,20,25,26 To determine if there 
were differences in dihydrotestosterone levels in control and 
previously pregnant HAF rats that could account for the dif-
ferences in MAP at 16 months of age, plasma dihydrotestos-
terone was measured. However, dihydrotestosterone was not 
different between virgin and previously pregnant HAF rats 
(virgin HAF: 102.8±22.9; previously pregnant HAF [n=6]: 
101.9±22.9 pg/mL; p=NS).
Body Composition, Prepregnancy, and Postdelivery
To determine whether pregnancy itself affected body com-
position in HAF rats that could impact later in life blood 
pressure, body weight, fat and lean masses, and their ratios 
to body weight were measured prepregnancy or 48 hours 
postdelivery in control or HAF rats and compared with 
age-matched virgin HAF rats. As shown in Table 1, be-
fore and after pregnancy, HAF rats had higher body weight 
than controls. Body weight increased similarly with time 
in both pregnant groups. Time and androgens provided the 
major differences between the groups, with no interactions 
noted. Changes in fat mass were affected only by time, not 
androgens. Fat mass factored for body weight was not af-
fected by pregnancy or time. Lean mass was higher in HAF 
rats than control before and after pregnancy, and both time 
and androgens were the major factors for the differences, 
with no interactions noted. When factor for body mass, only 
androgens were the main factor for differences between 
control and HAF pregnant rats with no interactions found. 
As shown in Table 2 comparing pregnant and virgin HAF 
rats, before pregnancy there were no differences in the rats. 
With time, both groups increased body weights to similar 
extent, and there was no difference in body weight gain. Fat 
mass did not increase to the same extent in pregnant HAF 
rats as in controls, but there was no interaction noted. When 
fat mass was factored for body weight there was interaction 
noted, however. Lean mass increased in both groups over 
the time of pregnancy with no interactions. However, when 
factored for body weight, there was interaction with time 
with pregnant groups increasing lean mass more than con-
trol virgin HAF.
Body Composition and Metabolic Factors With Aging
To determine if there were differences in body composition 
with aging in HAF rats that may contribute to the differences 
in MAP, fat, and lean masses were measured. As shown in 
Table 3, both age and pregnancy status significantly affected 
body weight with no significant interaction, with body weight 
being similar in virgin and previously pregnant HAF at 10 
months but was reduced in previously pregnant HAF at 16 
months compared with virgins. Fat mass was higher in 16 
months old groups, whereas lean mass was not different 
among the groups. Lean mass was not different among the 
groups, but lean mass/body weight ratios were significantly 
lower in HAF at 16 months than the other groups. Fat mass, 
fat mass/body weight ratios, and lean mass/body weight 
ratios were only affected by time, not parity, with no signifi-
cant interactions.
To determine if there were differences in insulin resistance 
between virgin and previously pregnant HAF rats, plasma in-




Figure 1. Number of pups per litter and body weights of hyperandrogenemic 
female (HAF) and control offspring. A, There were no differences in average 
numbers of pups per litter between control and HAF dams (P=NS). B, Birth 
weights were lower in male and female HAF offspring than control offspring, 
and female HAF birth weights were lower than male HAF. C, At postnatal 
day 2, body weights remained lower in male and female HAF offspring than 
controls. Statistical significance using the Student t test (A) or 2-way ANOVA 
(B and C) was defined as P≤0.05. A, P≤0.05 compared with control males; B, 
P≤0.05 compared with HAF male offspring; C, P≤0.05 compared with control 
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performed. Plasma insulin was not different between the HAF 
groups at 16 months of age (virgin HAF [n=14]: 1.3±0.2; pre-
viously pregnant HAF [n=10]: 1.1±0.2 ng/mL; P=NS). Oral 
glucose tolerance, as shown in Figure S3, was not affected by 
previous pregnancy in HAF rats at either 10 or 16 months of 
age. Fasting blood glucose level was also not elevated in ei-
ther HAF groups at either age, showing rats were not diabetic.
Proteinuria and Nitrate/Nitrite Excretion
We determined if proteinuria increased with aging in HAF 
rats and whether pregnancy affected the levels. As shown in 
Figure 3A, both aging and parity impacted the level of pro-
teinuria with no interactions noted. Proteinuria was higher in 
16-month-old HAF virgins than virgin or previously pregnant 
HAF at 10 months, and previous pregnancy attenuated pro-
teinuria in HAF rats, 16 months of age.
As shown in Figure 3B, there was a significant interaction 
between age and parity on nitrate/nitrite excretion in virgin 
and previously pregnant HAF rats, aged 10 and 16 months. 
Nitrate/nitrite excretion decreased in virgin HAF, aged 16 
months, compared with virgin and previously pregnant HAF 
at 10 months. However, by 16 months of age, previous preg-
nancy increased nitrate/nitrite excretion in HAF to levels sim-
ilar to HAF groups at 10 months of age.
Intrarenal Gene Expression Analyses
To determine if there were differences in intrarenal gene ex-
pression that could contribute to differences in MAP among 
virgin and previously pregnant control and HAF rats, 16 
months of age, we evaluated mRNA expression of eNOS, 
and components of the renin-angiotensin system (RAS) and 
the ET system. As shown in Table 4, eNOS expression was 
decreased in virgin HAFs compared with controls, whereas 
pregnancy normalized eNOS in HAF. In components of the 
RAS, renin, and AT1aR mRNA were lower, and angioten-
sinogen mRNA was higher in both HAF groups. Pregnancy 
tended to further reduce AT1aR expression in HAF, and ACE 
was also lower in previously pregnant HAF than virgin HAF. 
Intrarenal pre-pro-ET-1 mRNA was higher in virgin HAF than 
controls or previously pregnant HAF, ET
A
R expression was 




Figure 2. Blood pressure in virgin and 
previously pregnant hyperandrogenemic 
female (HAF) and control rats at 10 or 16 mo 
of age. Statistical significance was determined 
by 2-way ANOVA with repeated measures 
and defined as P≤0.05. A, At 16 mo of age, 
mean arterial pressure (MAP) was similar in 
previously pregnant and virgin controls. MAP in 
previously pregnant HAF rats was not different 
than virgin controls but was higher than 
previously pregnant controls. MAP was higher 
in virgin HAF rats than all controls or previously 
pregnant HAF rats. B, MAP at 10 mo of age 
was higher in virgin and previously pregnant 
HAF rats than in virgin or previously pregnant 
controls. Pregnancy had no effect on MAP in 
either controls or HAF rats. C, Comparison 
of MAP at 10 and 16 mo of age in virgin and 
previously pregnant HAF rats. MAP was not 
different in previously pregnant HAF rats at 
16 mo of age compared with either virgins or 
previously pregnant HAF rats at 10 mo of age. 
However, MAP increased in virgin HAF rats 
between 10 and 16 mo of age. D, Comparison 
of systolic blood pressure (SBP) at 10 and 16 
mo of age in virgin and previously pregnant 
HAF rats. SBP was not different in previously 
pregnant HAF rats at 16 mo of age compared 
with either virgins or previously pregnant HAF 
rats at 10 mo of age. However, SBP increased 
in virgin HAF rats between 10 and 16 mo of 
age, and there was significant interaction with 
age and parity. E, Comparison of diastolic 
blood pressure (DBP) at 10 mo and 16 mo of 
age in virgin and previously pregnant HAF rats. 
DBP was not different in vigin or previously 
pregnant control rats at 10 or 16 mo of age. 
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but ET
B
R expression was lower in virgin HAF than controls or 
previously pregnant HAF.
Discussion
In this study, we tested the hypothesis that previous pregnancy 
would protect HAF rats from age-related hypertension. In fact, 
we found that (1) previous pregnancy in aging (16 months) 
HAF rats attenuated the hypertension found in age-matched 
virgins; (2) along with the reduction in blood pressure, previ-
ously pregnant HAF exhibit upregulation of intrarenal eNOS 
and ET
B
 receptor mRNA, along with downregulation of renin, 
ET
A
R, and AT1aR mRNA; (3) similarly, previously pregnant 
HAF rats exhibited a reduction in proteinuria and an increase 
in nitrate/nitrite excretion compared with virgin HAF rats; (4) 
before cessation of estrous cycling (10 months of age), there 
were no differences in blood pressure, proteinuria, or nitrate/
nitrite excretion in HAF rats regardless of pregnancy status; 
(5) male and female offspring born to HAF rats exhibited in-
trauterine growth restriction with lower birth weights, com-
pared with offspring born to control females.
The HAF rat is a well-characterized model that mimics 
many of the symptoms of women with PCOS, including in-
sulin resistance, hyperlipidemia, and elevated blood pres-
sure as early as 14 to 16 weeks of age.19 However, this is the 
first study, to our knowledge, to address the cardiovascular-
metabolic consequences of pregnancy using the HAF model. 
Common rodent models that seek to study the outcomes of 
hyperandrogenemic pregnancy on dams or the offspring in-
ject dams with testosterone beginning on gestational days 15 
to 17 only, and at doses that are significantly higher than the 
dihydrotestosterone doses we use for the HAF model (0.5 mg/
kg per day testosterone versus 0.25–0.33 μg/kg per day dihy-
drotestosterone).27,28 Our HAF rats are treated with dihydro-
testosterone beginning at 4 weeks of age (prepubertal) and 
throughout pregnancy and lactation. Thus, the HAF model 
better mimics pregnancy in women with PCOS than the late 
gestation androgen model.
In studying the potential changes in gene expression that 
could contribute to hypertension in virgin HAF rats and pro-
tection seen in previously pregnant HAF, we measured mRNA 
expression of both vasodilators and vasoconstrictors. We 
found that in previously pregnant HAF rats, there was an in-
crease in eNOS mRNA expression that was supported by an 
increase in nitrate/nitrite excretion, an index of NO. Whether 
eNOS activity is increased in previously pregnant rats HAF 
will need to be determined in future studies. However, we 
found previously that the components of the NADPH oxidase 
system are upregulated in young HAF rats.19 Since aging is as-
sociated with increased oxidative stress, it is also possible then 
that in aging virgin HAF rats, any NO being produced may be 
scavenged by superoxide, produced by NADPH oxidase, thus 
reducing the bioavailability of NO to cause vasodilation and 
contributing to their elevated blood pressure. Whether oxida-
tive stress increases with aging in virgin HAF rats to a greater 
extent than in previously pregnant HAF will also need to be 
determined to further identify the mechanisms responsible for 
their hypertension.
Young women with PCOS have increased plasma renin 
levels and activity29,30 and increased plasma prorenin.31 In con-
trast, in the present study in the aging HAF rats, we found 
that intrarenal renin mRNA expression was decreased in both 
virgin and previously pregnant rats. Androgens are known to 
upregulate intrarenal angiotensinogen, and we have shown 
previously that angiotensinogen was elevated by 10-fold at 
14 to 16 weeks of age in virgin HAF rats.19,32 In the present 
study, angiotensinogen was also increased by 8- to 9-fold but 
was similar in both HAF groups. Renin is the rate-limiting 
step in the synthesis of Ang II (angiotensin II), but if renin 
is not working at Vmax, then the lower levels of renin may 
be offset by the significant increases in angiotensinogen sub-
strate that would support higher Ang II levels in the HAF 
rats. In young PCOS women, ACE gene polymorphism was 
associated with adverse metabolic comorbidities.33,34 In the 
present study, intrarenal ACE mRNA tended to be decreased 
in previously pregnant HAF rats compared with virgins. 
Similarly, intrarenal AT1aR mRNA expression was decreased 
significantly in previously pregnant HAF rats compared with 
virgins. Enalapril (ACE inhibitor) and telmisartan (AT
1
R an-
tagonist) were shown by others to cause significant decreases 
in BP in HAF rats or PCOS women, respectively.25,35 Taken 
together, these data support that the RAS may contribute to 
the elevated blood pressure in HAF rats, but whether virgin 
HAF has higher Ang II than previously pregnant rats needs to 
be determined. Previously pregnant HAF rats may also have 
higher levels of the vasodilator arm of the RAS, Ang(1–7) or 
AT2R, that could contribute to their attenuated blood pressure 
compared with virgins, and will also need to be determined.
Young women with PCOS and female to male transsexu-
als have elevated levels of endothelin.36,37 There are no stud-
ies to our knowledge on the levels of ET-1 in postmenopausal 
PCOS women. Alexander et al38 reported that Ang II stimu-
lates intrarenal ET-1 production. Androgens then may directly 
Table 3. BWs and Body Composition of Virgin and Previously Pregnant HAF Rats at 10 and 16 Months of Age
Parameter
HAF, 10 mo HAF, 10 mo HAF, 16 mo HAF, 16 mo
Interaction Parity AgeVirgin Previously Pregnant Virgin Previously Pregnant
BW, g 399.5±6.4 392.3±5.2 427.8±7.4 392.5±16.7 P=0.16 P=0.02 P=0.02
Fat mass, g 56.2±3.8 54.7±4.2 81.6±8.7 80.5±7.8 P=0.95 P=0.82 P<0.01
Lean mass, g 317.2±5.4 315.6±5.6 321.1±10.5 321.1±10.5 P=0.34 P=0.25 P=0.64
Fat mass/BW ratio 0.14±0.01 0.14±0.01 0.19±0.02 0.20±0.01 P=0.78 P=0.86 P<0.01
Lean mass/BW ratio 0.80±0.01 0.80±0.01 0.75±0.02 0.75±0.01 P=0.71 P=0.75 P<0.01
Values represent mean±SEM. Fat and lean masses were determined by Echo-MRI, as described in Methods. Statistical analyses were performed by 2-way ANOVA; 
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stimulate endothelin synthesis or may stimulate the RAS to in-
crease endothelin, thus leading to the expression of 2 powerful 
vasoconstrictors that could impact BP in women with PCOS.39 
In the present study, there were no differences in levels of 
plasma dihydrotestosterone between the virgin and previously 
pregnant HAF rats, and pre-pro-ET-1 mRNA expression was 
upregulated to similar levels in both groups as well, suggesting 
that intrarenal ET-1 may be similar in the groups. However, 
intrarenal ET
A
R expression was lower and ET
B
R expression 
was higher in previously pregnant HAF, both suggesting these 
differences could contribute to the higher blood pressure in 
virgin HAF. Interestingly, Usselman et al32,37 reported that 
young PCOS women have elevated ET-1 that endothelial vas-
odilation via ET
B
R predominated but is attenuated compared 
with controls and that the effect was independent of NO, since 
nitro-L-arginine methyl esther had no effect on vasodilatory 
response to ET-1. Additional studies will be necessary to deter-
mine the full contribution of endothelin and endothelin recep-
tors to the age-related hypertension in HAF rats.
One interesting finding for the present studies is that the 
difference in hypertension between previously pregnant and 
virgin HAF rats does not occur until after cessation of es-
trous cycling and with advanced aging. At 10 months of age, 
when the rats are still cycling, the blood pressure, although 
elevated compared with controls, was not different between 
previously pregnant and virgin HAF rats. We have shown pre-
viously that the HAF rat model ceases to cycle by 13 months 
of age.22 If loss of estrogens in the face of increased androgens 
was the mechanism by which blood pressure increased with 
aging in the HAF model, one would expect that blood pressure 
would also rise in previously pregnant HAF rats that have also 
stopped estrous cycling. Thus, it is not likely that estrogens 
played a role in the age-related protection against the increase 
in blood pressure in the previously pregnant HAF rats.
Women with PCOS often have difficulty becoming preg-
nant and require assisted reproduction.40 Just as in PCOS 
women, our HAF rat model also has reproductive difficulties 
with only 60% of those placed with a male becoming pregnant, 
compared with >99% of control Sprague-Dawley rats that be-
come pregnant. Another consequence of hyperandrogenemia 
during pregnancy was the lower birth weights of both male 
and female offspring of the HAF rats. In women with PCOS, 
their children are born either small for gestational age,41,42 as 
in our study, or large for gestational age.40 If PCOS women 
have elevated glucose associated with obesity and insulin re-
sistance, their children may be born large for gestational age.40 
Gopalakrishnan et al27 reported that testosterone supplements 
given from day 15 to 19 of pregnancy in rats caused a reduc-
tion in both placental weights and fetal weights and was as-
sociated with increased expression of markers of hypoxia, 
such as hypoxia-inducible factor 1α, along with reductions 
in uterine blood flow.27 Thus, the presence of elevated andro-
gens in the HAF rats may have contributed to the lower birth 
weights in their offspring.
We have shown previously that our model of hyperandro-
genemia has insulin resistance (elevated insulin levels) but no 
increase in fasting glucose both as young adults and following 
estrous cycling,19,22 so the HAF rats are not diabetic. We have 
not measured insulin or glucose handling during pregnancy in 
the HAF model, but since the offspring are born small for ges-
tational age, it is not likely the dams have gestational hyper-
glycemia. We also have not measured blood pressure during 
the pregnancy in our HAF rats. However, it is also not likely 
that pregnancy in these rats is associated with preeclampsia-
like symptoms, otherwise the dams should have early CVD 
and hypertension, as is common for women with pree-
clampsia.43 In this regard, the HAF rat model may be similar to 
A
B
Figure 3. Proteinuria and nitrate/nitrite excretion in virgin and previously 
pregnant hyperandrogenemic female rats at 10 and 16 mo of age. Proteinuria 
(A) and nitrate/nitrite (UNOx) (B) excretion in virgin and previously pregnant 
hyperandrogenemic female (HAF) rats at 10 and 16 mo of age. A, Protein 
excretion was not different between previously pregnant and virgin HAF 
rats at 10 mo of age. At 16 mo, protein excretion was higher in virgin HAF 
compared with all HAF rats at 10 mo. Proteinuria in previously pregnant HAF 
at 16 mo was similar to HAF rats at 10 mo and was lower than age-matched 
virgin HAF rats. Statistical significance was determined by 2-way ANOVA with 
Fisher LSD post hoc test and defined as P≤0.05. B, Nitrate/nitrite excretion 
was not different in virgin and previously pregnant HAF rats at 10 mo of age, 
or virgin HAF rats at 16 mo of age. However, nitrate/nitrate excretion was 
higher in previously pregnant HAF, aged 16 mo, than age-matched virgin HAF 
rats. Statistical significance was determined by 2-way ANOVA with Fisher 
LSD post hoc test and defined as P≤0.05. A, P≤0.05, compared with virgin 
HAF rats, 10 mo; B, P≤0.05, compared with previously pregnant HAF, 10 mo; 




 http://ahajournals.org by on A
ugust 9, 2020
8  Hypertension  September 2020
the spontaneously hypertensive rat that is hypertensive before 
pregnancy but exhibits a reduction in blood pressure in late 
pregnancy,44 and multiple pregnancies have no adverse effect 
on their renal function or blood pressure.45 Similarly, Hu et al10 
performed ambulatory blood pressure measurements in PCOS 
and control women as they progressed throughout their preg-
nancies. They found that PCOS women had higher blood pres-
sure in the first trimester (11–13 weeks gestation) than control 
women, but there was no gestational effect, that is, pregnancy 
per se did not further increase blood pressure.10 In addition, 
the average blood pressures in the PCOS women did not reach 
the levels required for treatment at that time (Seventh Report 
of the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure).46
To our knowledge, there are no studies in which the amounts 
of fat mass and lean mass were measured in PCOS women, pre-
pregnancy, and postpregnancy. We performed these studies in 
our HAF dams to determine if the pregnancy itself reduced the 
amount of body fat mass compared with the virgin HAF con-
trols. It was interesting that the levels of fat mass/body weight 
ratio increased and the lean mass/body ratio decreased so sig-
nificantly during the time of pregnancy in the HAF and control 
rats. However, these differences in fat and lean masses observed 
when the rats were young were not present at 10 and 16 months 
of age. Thus, the data do not support a role for improved body 
composition during pregnancy as mediating the lower blood 
pressure in previously pregnant HAF rats.
One caveat of the present study is that ≈60% of the HAF 
rats, when placed with a male, became pregnant. Thus, it is 
possible that the 60% had a more favorable cardiovascular/
reproductive system that allowed them to become pregnant 
and thus with aging also exhibited lower blood pressure. 
However, there were no differences in the prepregnancy 
body weights or body composition, lean or fat mass, between 
the HAF rats, whether they were scheduled to be mated or 
remain virgins, that could account for the difficulty in be-
coming pregnant. Female rats can become pseudopregnant, 
but we have no evidence that this occurred in HAF rats, and 
only rats that became pregnant and delivered pups were in-
cluded in the present study.
Perspectives
In the present study, we tested the hypothesis that previous 
pregnancy would protect against age-related hypertension in 
our model of PCOS. Despite no differences in dihydrotestos-
terone levels, body composition, or insulin resistance, hyper-
tension was indeed attenuated in previously pregnant HAF rats 
compared with virgin HAF. The mechanism(s) responsible for 
the protection may be differential intrarenal regulation of the 
NO, endothelin, and renin-angiotensin systems.
While some studies show PCOS women are at increased 
risk to develop preeclampsia during pregnancy and they may 
take longer to become pregnant, their pregnancy outcomes 
are not different than control women.8,18,47 Thus studies need 
to be performed in aging PCOS women who have been preg-
nant and compare them to PCOS women who have never 
been pregnant to determine their relative risks of developing 
postmenopausal hypertension and CVD compared with the 
general population. Now that PCOS diagnosis guidelines 
have been in place >15 years, these studies should be forth-
coming, but in addition to verification of pregnancy, the new 
studies need to also verify that the women studied actually 
had PCOS as defined by increased androgens during their re-
productive years.
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Table 4. Intrarenal mRNA Expression of eNOS, Components of the Renin-Angiotensin System and Endothelin System in Virgin and Previously Pregnant Control Rats, 
Aged 16 Months, Compared With Age-Matched Virgin and Previously Pregnant HAF Rats
Renal mRNA Expression (ΔΔC
T
/
Geometric Mean of housekeeping genes)
Control HAF
Virgin (n=6) Previously Pregnant (n=7) Virgin (n=12) Previously Pregnant (n=9)
eNOS (NOS3) 1.00±0.05 0.98±0.08 0.82±0.04*,† 1.03±0.04‡
Renin 1.00±0.13 0.62±0.07* 0.48±0.06* 0.57±0.09*
Angiotensinogen 1.00±0.13 0.87±0.08 8.16±1.30*,† 9.31±1.30*,†
ACE 1.00±0.08 0.97±0.06 1.10±0.08 0.82±0.09‡
AT1aR 1.00±0.05 0.93±0.07 0.69±0.05*,† 0.52±0.03*,†,‡
Pre-pro-ET-1 1.00±0.07 1.05±0.07 1.68±0.20*,† 1.45±0.10
ET
A
R 1.00±0.06 1.00±0.08 1.08±0.08 0.91±0.06‡
ET
B
R 1.00±0.05 0.96±0.07 0.80±0.02*,† 0.94±0.05‡
Expression values were normalized to the geometric mean of 4 housekeeping genes, as described in Methods in the Data Supplement. Values represent mean±SEM. 
Statistical analyses were performed using 2-way ANOVA followed by uncorrected Fisher LSD test; significance was defined as P≤0.05. ACE indicates angiotensin 
I–converting enzyme; AT1aR, angiotensin 1a receptor; eNOS, endothelial nitric oxide synthase; ET
A
R, endothelin A receptor; ET
B
R, endothelin B receptor; HAF, 
hyperandrogenemic female; and pre-pro-ET-1, pre-pro-endothelin-1.
*P≤0.05, compared with virgin controls.
†P≤0.05, compared with previously pregnant controls.
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What Is New?
•	This is the first study to evaluate the consequences of prior pregnancy 
on age-related hypertension in a rat model of hyperandrogenemia that 
mimics many of the characteristics of women with polycystic ovary syn-
drome.
•	Previous pregnancy attenuated the hypertension in hyperandrogenemic 
female rats, aged 16 months, compared with virgin controls.
•	Mechanisms responsible are likely differential regulation of intrarenal 
vasoconstrictors/vasodilators.
What Is Relevant?
•	There are no studies that have evaluated the consequences of preg-
nancy on cardiovascular disease and hypertension in aging, post-
menopausal women with polycystic ovary syndrome, who have hy-
perandrogenemia.
Summary
Previous pregnancy protects hyperandrogenemic female rats 
from age-related hypertension. The mechanisms for the attenu-
ation of the hypertension are not due to different levels of andro-
gens, body composition (fat mass and lean mass), insulin levels, 
or glucose metabolism but rather are likely due to increased vas-
odilator systems (eNOS [endothelial nitric oxide synthase], ET
B
R 
[endothelin B receptor], renin-angiotensin system) and attenu-
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